Ratings XOMA Corporation Nasdaq

Equities

XOMAP

US98419J3059

Delayed Nasdaq Other stock markets 21:30:01 22/05/2024 BST			5-day change	1st Jan Change
25.1 ^USD	+0.32%		-0.63%	-1.22%

05-09	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT
05-09	XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XOMA CORPORATION	-1.22%	293M	-
VERTEX PHARMACEUTICALS INCORPORATED	+10.63%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+12.26%	106B	B+
BIONTECH SE	-5.59%	24.69B	B+
ARGENX SE	-1.60%	21.97B	B
GENMAB A/S	-5.24%	19.27B	A-
BEIGENE, LTD.	-11.04%	17.56B	B
WUXI APPTEC CO., LTD.	-39.36%	17.32B	A-
NEUROCRINE BIOSCIENCES, INC.	+5.91%	14.03B	C+
SAREPTA THERAPEUTICS, INC.	+33.49%	12.13B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes